Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2026-09-24 17:35:13 ET · period of report 2026-09-22 · accession 0001193125-26-401237 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-24 17:35 | 2026-09-22 | CRSP | KASINGER JAMES R. | GC, Sec | M - OptEx | $13.62 | +10.4K | 105.2K | +11% | +$141.6K |
| DT | 2026-09-24 17:35 | 2026-09-22 | CRSP | KASINGER JAMES R. | GC, Sec | S - Sale+OE | $60.24 | -10.4K | 94.8K | -10% | -$626.5K |
| DT | 2026-09-24 17:35 | 2026-09-22 | CRSP | KASINGER JAMES R. | GC, Sec | M - OptEx | $0.00 | -10.4K | 83.2K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-09-22 | M | A | 10,400 | $13.62 | 105,184 | D | — | — | (F1) Includes 476 shares acquired under the CRISPR Therapeutics AG 2026 Employee Stock Purchase Plan. |
| 2 | Common | Common Shares | 2026-09-22 | S | D | 10,400 | $60.24 | 94,784 | D | — | — | (F2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-09-22 | M | D | 10,400 | $0.00 | 83,232 | D | $13.62 · — to 2027-05-31 | 10,400 Common Shares | (F4) This option was granted on May 31, 2017 with respect to 123,000 Common Shares of which 25% shall vest on May 31, 2018 and the remaining 75% shall vest monthly thereafter for 36 months. |